Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Spark Therapeutics, Inc. (ONCE) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/17/2019 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Amended and Restated Certificate of Incorporation of the Company (filed herewith)",
"Bylaws of the Company (filed herewith)"
09/05/2019 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
07/08/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment No. 1 to Agreement and Plan of Merger, among Spark Therapeutics, Inc., Roche Holdings, Inc. and 022019 Merger Subsidiary, Inc. (incorporated by reference to Exhibit (d)(3) to the Schedule TO)"
02/25/2019 8-K Quarterly results
02/19/2019 8-K Quarterly results
01/07/2019 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Spark Therapeutics, Inc. Presentation for the 2019 J.P. Morgan Healthcare Conference"
11/23/2018 8-K Other Events
Docs: "FORM 8-K"
11/15/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
11/06/2018 8-K Quarterly results
Docs: "Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress PHILADELPHIA, Nov. 6, 2018 - Spark Therapeutics , a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for the third quarter of 2018 and recent business progress. “In the third quarter, we made significant progress with LUXTURNA both in terms of sales growth and medical policy coverage expansion. We have also made important advancements in preparing for the Phase 3 run-in study of investigational SPK-8011 for hemophilia A before year end,” said Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics. “Additionally, we continue to capitalize on our proven and proprietary adeno-ass..."
08/07/2018 8-K Quarterly results
Docs: "Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show:"
07/09/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
05/31/2018 8-K Submission of Matters to a Vote of Security Holders
05/23/2018 8-K Completion of Acquisition or Disposition of Assets
05/08/2018 8-K Quarterly results
Docs: "Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress Achieved historic milestone with first patients treated with LUXTURNA™ PHILADELPHIA, May 8, 2018 - Spark Therapeutics , a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for the first quarter of 2018 and recent business progress. “We are encouraged by the initial launch of LUXTURNA™ . We are pleased that three patients were treated with LUXTURNA in the first quarter as we remain focused on working closely with treatment centers and payers to support timely access to the product,” said Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics. “Additionally, we progressed our pip..."
04/30/2018 8-K Quarterly results
02/20/2018 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress U.S. Food and Drug Administration grants breakthrough therapy designation to SPK-8011 for hemophilia A PHILADELPHIA, Feb. 20, 2018 - Spark Therapeutics , a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for 2017 and recent business progress. “The landmark approval of LUXTURNA™ in December as the first gene therapy for a genetic disease in the U.S. topped another year of great progress for Spark Therapeutics,” said Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics. “We have built a fully integrated company dedicated to discovering, developing and delivering one-time treatments that provide ..."
01/24/2018 8-K Entry into a Material Definitive Agreement
01/08/2018 8-K Results of Operations and Financial Condition
Docs: "FORM 8-K"
01/04/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/03/2018 8-K Quarterly results
12/19/2017 8-K Other Events
11/27/2017 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
11/07/2017 8-K Quarterly results
Docs: "Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress PHILADELPHIA, Nov. 7, 2017 - Spark Therapeutics , a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today financial results for the third quarter of 2017 and recent business progress. “We have made important progress over the last several months with investigational LUXTURNA™ for patients with biallelic RPE65-mediated inherited retinal disease ,” said Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics. “We are very pleased with the outcome of the Advisory Committee meeting, including the unanimous vote to recommend approval of LUXTURNA, with the completion of FDA pre-approval inspections of our manufacturing facili..."
08/04/2017 8-K Quarterly results
08/02/2017 8-K Quarterly results
Docs: "Spark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress Preliminary interim data for SPK-8011 Phase 1/2 dose-escalation clinical trial in hemophilia A show initial human proof-of-concept in three participants In the two participants at the initial dose, stable factor VIII levels average greater than 12 percent with no spontaneous bleeds Investigational LUXTURNA TM Prescription Drug User Fee Act date set for Jan. 12, 2018; granted rare pediatric disease designation by FDA PHILADELPHIA, Aug. 2, 2017 - Spark Therapeutics , a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today financial results for the second quarter of 2017 and recent business progress. “This has been an unprecedented time a..."
07/21/2017 8-K Form 8-K - Current report:
07/17/2017 8-K Form 8-K - Current report:
06/09/2017 8-K Termination of a Material Definitive Agreement
06/08/2017 8-K Form 8-K - Current report
06/02/2017 8-K Form 8-K - Current report
05/09/2017 8-K Form 8-K - Current report
02/22/2017 8-K Form 8-K - Current report
12/08/2016 8-K Form 8-K - Current report
12/05/2016 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy